Связь между сердечно-сосудистым риском и неалкогольной жировой болезнью печени

Связь между сердечно-сосудистым риском и неалкогольной жировой болезнью печени

Автор: Каршина О.О., Сабиров И.С., Кундашев У.К., Мохаммад Э.А., Инаркиев Р.А., Фазилова С.С.

Журнал: Бюллетень науки и практики @bulletennauki

Рубрика: Медицинские науки

Статья в выпуске: 12 т.10, 2024 года.

Бесплатный доступ

Неалкогольная жировая болезнь печени (НАЖБП) может рассматриваться, как самостоятельное заболевание или как компонент метаболического синдрома, и связана с такими состояниями, как сахарный диабет, ожирение, нарушения липидного обмена и артериальная гипертензия. НАЖБП и атеросклеротически обусловленные сердечно-сосудистые заболевания (АССЗ) имеют общие факторы риска, включая ожирение, сахарный диабет и нарушение липидного обмена. В настоящее время широко распространена гипотеза о том, что НАЖБП является независимым сердечно-сосудистым фактором риска, причем эта связь влияет на возникновение или усугубление атеросклеротического процесса. Это имеет большое значение, для диагностики и оценки риска сердечно-сосудистых заболеваний у пациентов с НАЖБП. Цель обзорного исследования заключается в анализе роли НАЖБП как фактора риска кардиоваскулярных заболеваний, связанных с метаболической дисфункцией. Основное внимание будет уделено распространённым сердечно-сосудистым проявлениям у пациентов с НАЖБП с целью выявления взаимосвязей между метаболическими нарушениями и развитием ССЗ.

Еще

Стеатоз печени, атеросклероз, сердечно-сосудистый риск, метаболический синдром, инсулинорезистентность

Короткий адрес: https://sciup.org/14132014

IDR: 14132014   |   DOI: 10.33619/2414-2948/109/40

Список литературы Связь между сердечно-сосудистым риском и неалкогольной жировой болезнью печени

  • Younossi Z. M., Golabi P., Paik J. M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review // Hepatology. 2023. V. 77. №4. P. 1335-1347. https://doi.org/10.1097/HEP.0000000000000004
  • Bellentani S. et al. Epidemiology of non-alcoholic fatty liver disease //Digestive diseases. -2010. V. 28. №1. P. 155-161. https://doi.org/10.1159/000282080
  • Scorletti E., Calder P. C., Byrne C. D. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments // Endocrine. 2011. V. 40. P. 332-343. https://doi.org/10.1007/s12020-011-9530-x
  • Hyogo H., Chayama K., Yamagishi S. Nonalcoholic fatty liver disease and cardiovascular disease // Current Pharmaceutical Design. 2014. V. 20. №14. P. 2403-2411. https://doi.org/10.2174/13816128113199990476
  • Loomba R., Sanyal A. J. The global NAFLD epidemic // Nature reviews Gastroenterology & hepatology. 2013. V. 10. №11. P. 686-690. https://doi.org/10.1038/nrgastro.2013.171
  • Kenchaiah S., Evans J. C., Levy D., Wilson P. W., Benjamin E. J., Larson M. G., Vasan R. S. Obesity and the risk of heart failure // New England Journal of Medicine. 2002. V. 347. №. 5. P. 305-313. https://doi.org/10.1056/NEJMoa020245
  • Сторожаков Г. И., Эттингер О. А. Поражение печени при хронической сердечной недостаточности // Сердечная недостаточность. 2005. Т. 6. №1. С. 32-37.
  • Гарбузенко Д. В. Мультиорганные гемодинамические нарушения при циррозе печени // Терапевтический архив. 2007. Т. 79. №2. С. 73-77.
  • Milic S., Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment // Digestive diseases. 2012. V. 30. №2. P. 158-162. https://doi.org/10.1159/000336669
  • Baran B., Akyuz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? // World Journal of Gastroenterology: WJG. 2014. V. 20. №39. P. 14219. https://doi.org/10.3748/wjg.v20.i39.14219
  • Paradis V. et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis // Hepatology. 2001. V. 34. №4. P. 738-744. https://doi.org/10.1053/jhep.2001.28055
  • Ekstedt M., Hagstrom H., Nasr P., Fredrikson M., Stal P., Kechagias S., Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up // Hepatology. 2015. V. 61. №5. P. 1547-1554. https://doi.org/10.1002/hep.27368
  • Lonardo A., Ballestri S., Marchesini G., Angulo P., Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome // Digestive and Liver disease. 2015. V. 47. №3. P. 181-190. https://doi.org/10.1016/j.dld.2014.09.020
  • Shields W. W. et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial // Therapeutic advances in gastroenterology. 2009. V. 2. №3. P. 157-163. https://doi.org/10.1177/1756283X09105462
  • Streba L. A. M., Vere C. C., Rogoveanu I., Streba C. T. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question // World journal of gastroenterology: WJG. 2015. V. 21. №14. P. 4103. https://doi: 10.3748/wjg.v21.i14.4103. https://doi.org/10.3748/wjg.v21.i14.4103
  • Stepanova M., Rafiq N., Younossi Z. M. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study // Gut. 2010. V. 59. №10. P. 1410-1415. https://doi.org/10.1136/gut.2010.213553
  • Rosso C., Mezzabotta L., Gaggini M., Salomone F., Gambino R., Marengo A., Bugianesi E. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease // Hepatology. 2016. V. 63. №1. P. 107-116. https://doi.org/10.1002/hep.28287
  • Korkmaz H., Unler G. K., Gokturk H. S., Schmidt W. E., Kebapcilar L. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test // European journal of gastroenterology & hepatology. 2015. V. 27. №10. P. 1137-1143. https://doi.org/10.1097/MEG.0000000000000407
  • Cetin E. G., Demir N., Sen I. The relationship between insulin resistance and liver damage in non-alcoholic fatty liver patients // The Medical Bulletin of Sisli Etfal Hospital. 2020. V. 54. №4. P. 411. https://doi.org/10.14744/SEMB.2018.83604
  • Matherly S. C., Puri P. Mechanisms of simple hepatic steatosis: not so simple after all // Clinics in Liver Disease. 2012. V. 16. №3. P. 505-524. https://doi.org/10.1016/j.cld.2012.05.005
  • Sahebkar A., Chew G. T., Watts G. F. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease // Expert opinion on pharmacotherapy. 2014. V. 15. №4. P. 493-503. https://doi.org/10.1517/14656566.2014.876992
  • Лазебник Л. Б., Туркина С. В. НАЖБП-ассоциированная коморбидность // Экспериментальная и клиническая гастроэнтерология. 2021. №10 (194). С. 5-13. https://doi.org/10.31146/1682-8658-есд-194-10-5-13
  • Wanless I. R., Lentz J. S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors // Hepatology. 1990. V. 12. №5. P. 1106-1110. https://doi.org/10.1002/hep.1840120505
  • DeFilippis A. P., Blaha M. J., Martin S. S., Reed R. M., Jones S. R., Nasir K., Budoff, M. J. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis // Atherosclerosis. 2013. V. 227. №2. P. 429-436. https://doi.org/10.1016/j.atherosclerosis.2013.01.022
  • Alkhouri N., Eng K., Lopez R., Nobili V. Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD) // Springerplus. 2014. V. 3. P. 1-9. https://doi.org/10.1186/2193-1801-3-407
  • Pierantonelli I., Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH // Transplantation. 2019. V. 103. №1. P. e1-e13. https://doi.org/10.1097/TP.0000000000002480
  • Peng C., Stewart A. G., Woodman O. L., Ritchie R. H., Qin C. X. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments // Frontiers in pharmacology. 2020. V. 11. P. 603926. https://doi.org/10.3389/fphar.2020.603926
  • Zhang T. S., Qin H. L., Wang T., Li H. T., Li H., Xia S. H., Xiang X. H. Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review // Springerplus. 2015. V. 4. P. 1-9. https://doi.org/10.1186/s40064-015-1542-1
  • Auguet T., Bertran L., Binetti J., Aguilar C., Martinez S., Sabench F., Richart C. Relationship between IL-8 circulating levels and TLR2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis // International journal of molecular sciences. 2020. V. 21. №11. P. 4189. https://doi.org/10.3390/ijms21114189
  • Hou X., Yin S., Ren R., Liu S., Yong L., Liu Y., Wang H. Myeloid-cell-specific IL-6 signaling promotes microRNA-223-enriched exosome production to attenuate NAFLD-Associated fibrosis // Hepatology. 2021. V. 74. №1. P. 116-132. https://doi.org/10.1002/hep.31658
  • Du Plessis J., Van Pelt J., Korf H., Mathieu C., Van der Schueren B., Lannoo M., Van der Merwe S. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease // Gastroenterology. 2015. V. 149. №3. P. 635-648. e14. https://doi.org/10.10537j.gastro.2015.05.044
  • Cabré N., Luciano-Mateo F., Fernández-Arroyo S., Baiges-Gayá G., Hernández-Aguilera A., Fibla M., Joven J. Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation // Metabolism. 2019. V. 99. P. 81-89. https://doi.org/10.1016/j.metabol.2019.07.002
  • Viglino D., Jullian-Desayes I., Minoves M., Aron-Wisnewsky J., Leroy V., Zarski J. P., Pépin J. L. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease // European Respiratory Journal. 2017. V. 49. №6. https://doi.org/10.1183/13993003.01923-2016
  • Yeniova A. O., Kü9ükazman M., Ata N., Dal K., Kefeli A., Basyigit S., Beyan E. High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease. 2014.
  • Zimmermann E., Anty R., Tordjman J., Verrijken A., Gual P., Tran A., Jess T. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients // Journal of hepatology. 2011. V. 55. №3. P. 660-665. https://doi.org/10.1016/jjhep.2010.12.017
  • Ridker P. M., Hennekens C. H., Buring J. E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women // New England journal of medicine. 2000. V. 342. №12. P. 836-843. https://doi.org/10.1056/NEJM200003233421202
  • Takaki A., Kawai D., Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH) // International journal of molecular sciences. 2013. V. 14. №10. P. 20704-20728. https://doi.org/10.3390/ijms141020704
  • Targher G., Bertolini L., Scala L., Cigolini M., Zenari L., Falezza G., Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease // Nutrition, Metabolism and Cardiovascular Diseases. 2007. V. 17. №7. P. 517-524. https://doi.org/10.1016Zj.numecd.2006.04.002
  • Li X. L., Sui J. Q., Lu L. L., Zhang N. N., Xu X., Dong Q. Y., Xuan S. Y. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review // Lipids in health and disease. 2016. V. 15. P. 1-8. https://doi.org/10.1186/s12944-016-0221-8
  • Katsarou A., Moustakas I. I., Pyrina I., Lembessis P., Koutsilieris M., Chatzigeorgiou A. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease // World journal of gastroenterology. 2020. V. 26. №17. P. 1993. https://doi.org/10.3748/wjg.v26.i17.1993
  • Nakashima M., Nakamura K., Nishihara T., Ichikawa K., Nakayama R., Takaya Y., Ito H. Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist // Nutrients. 2023. V. 15. №3. P. 748. https://doi.org/10.3390/nu15030748
  • Motamed N., Rabiee B., Poustchi H., Dehestani B., Hemasi G. R., Khonsari M. R., Zamani F. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases // Clinics and research in hepatology and gastroenterology. 2017. V. 41. №1. P. 31-38.
  • Wu S., Wu F., Ding Y., Hou J., Bi J., Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis // Scientific reports. 2016. V. 6. №1. P. 33386. https://doi.org/10.1038/srep33386
  • Hamaguchi M., Takeda N., Kojima T., Ohbora A., Kato T., Sarui H., Takeda J. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome // World journal of gastroenterology: WJG. 2012. V. 18. №13. P. 1508. https://doi.org/10.3748/wjg.v18.i13.1508
  • Lallukka S., Yki-Jarvinen H. Non-alcoholic fatty liver disease and risk of type 2 diabetes // Best practice & research Clinical endocrinology & metabolism. 2016. V. 30. №3. P. 385-395. https://doi.org/10.1016Zj.beem.2016.06.006
  • Ekstedt, M., Franzen, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. Long-term follow-up of patients with NAFLD and elevated liver enzymes // Hepatology. 2006. V. 44. №4. P. 865-873. https://doi.org/10.1002/hep.21327
  • Stamler J., Vaccaro O., Neaton J. D., Wentworth D., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial // Diabetes care. 1993. V. 16. №2. P. 434-444. https://doi.org/10.2337/diacare.16.2.434
  • Schattenberg J. M., Allen A. M., Jarvis H., Zelber-Sagi S., Cusi K., Dillon J. F., Lazarus J. V. A multistakeholder approach to innovations in NAFLD care // Communications medicine. 2023. V. 3. №1. P. 1. https://doi.org/10.1038/s43856-022-00228-y
  • Ballestri S., Zona S., Targher G., Romagnoli D., Baldelli E., Nascimbeni F., Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta - analysis // Journal of gastroenterology and hepatology. 2016. V. 31. №5. P. 936-944. https://doi.org/10.1111/jgh.13264
  • Gami A. S., Witt B. J., Howard D. E., Erwin P. J., Gami L. A., Somers V. K., Montori V. M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies // Journal of the American College of Cardiology. 2007. V. 49. №4. P. 403-414.
  • Targher G., Byrne C. D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis // Journal of hepatology. 2016. V. 65. №3. P. 589-600. https://doi.org/10.1016/jjhep.2016.05.013
  • Baharvand-Ahmadi B., Sharifi K., Namdari M. Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease // ARYA atherosclerosis. 2016. V. 12. №4. P. 201.
  • Ajmal M. R., Yaccha M., Malik M. A., Rabbani M. U., Ahmad I., Isalm N., Abdali N. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-a // indian heart journal. 2014. V. 66. №6. P. 574-579. https://doi.org/10.1016/j.ihj.2014.08.006
  • Armstrong M. J., Adams L. A., Canbay A., Syn W. K. Extrahepatic complications of nonalcoholic fatty liver disease // Hepatology. 2014. V. 59. №3. P. 1174-1197. https://doi.org/10.1002/hep.26717
  • Choi D. H., Lee S. J., Kang C. D., Park M. O., Choi D. W., Kim T. S., Lee J. W. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans // World Journal of Gastroenterology: WJG. 2013. V. 19. №38. P. 6453. https://doi.org/10.3748/wjg.v19.i38.6453
  • Perera N., Indrakumar J., Abeysinghe W. V., Fernando V., Samaraweera W. M., Lawrence J. S. Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka // BMC Cardiovascular Disorders. 2016. V. 16. P. 1-6. https://doi.org/10.1186/s12872-016-0212-8
  • Assy N., Djibre A., Farah R., Grosovski M., Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease // Radiology. 2010. V. 254. №2. P. 393-400. https://doi.org/10.1148/radiol.09090769
  • Kaymako S., Lu A. О. Measurement of the coronary flow velocity reserve in patients with non-alcoholic fatty liver disease // Turk J Gastroenterol. 2012. V. 23. №6. P. 720-726. https://doi.org/10.4318/tjg.2012.0489
  • Karajamaki A. J., Patsi O. P., Savolainen M., Kesaniemi Y. A., Huikuri H., Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study) // PloS one. 2015. V. 10. №11. P. e0142937. https://doi.org/10.1371/journal.pone.0142937
  • Tsang W. C., Ng W. F., Wu P. Y., Chow D. A., Li E. T. H., Wong T. C Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis // Journal of gastroenterology and hepatology. 2006. V. 21. №1. P. 116-121. https://doi.org/10.1111/j.1440-1746.2005.04146.x
  • Sorrentino P., Terracciano L., D'angelo S., Ferbo U., Bracigliano A., Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension // Official journal of the American College of Gastroenterology! ACG. 2010. V. 105. №2. P. 336-344. https://doi.org/10.1038/ajg.2009.587
  • Zhang T., Zhang C., Zhang Y., Tang F., Li H., Zhang Q., Xue F. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study // Atherosclerosis. 2015. V. 240. №1. P. 144-148. https://doi. org/10.1016/j. atherosclerosis.2015.02.049
  • Лазебник Л. Б., Чихирева Л. Н., Чихирев О. А., Ли Е. Д. Выбор антигипертезивной терапии при различных стадиях метаболически ассоциированной стеатозной болезни печени // Экспериментальная и клиническая гастроэнтерология. 2023. №11 (219). С. 52-61. https://doi.org/10.31146/1682-8658-ecg-219-11-52-61
  • Сабиров И. С., Каршина О. О., Сабирова А. И., Халматов А. Н. Метаболически ассоциированная жировая болезнь печени и пожилой возраст // Экспериментальная и клиническая гастроэнтерология. 2024. №3. С. 25-32. https://doi.org/10.31146/1682-8658-ecg-223-3-25-32
  • Kim H. C., Kim D. J., Huh K. B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome // Atherosclerosis. 2009. V. 204. №2. P. 521-525. https://doi.org/10.1016/j.atherosclerosis.2008.09.012
  • Salvi P., Ruffini R., Agnoletti D., Magnani E., Pagliarani G., Comandini G., Pazzi P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study // Journal of hypertension. 2010. V. 28. №8. P. 1699-1707. https://doi.org/10.1097/HJH.0b013e32833a7de6
  • Shiotani A., Motoyama M., Matsuda T., Miyanishi T. Brachial-ankle pulse wave velocity in Japanese university students // Internal medicine. 2005. V. 44. №7. P. 696-701. https://doi.org/10.2169/internalmedicine.44.696
  • Lee Y. J., Shim J. Y., Moon B. S., Shin Y. H., Jung D. H., Lee J. H., Lee H. R. The relationship between arterial stiffness and nonalcoholic fatty liver disease // Digestive diseases and sciences. 2012. V. 57. P. 196-203. https://doi.org/10.1007/s10620-011-1819-3
  • Laurent S., Boutouyrie P., Lacolley P. Structural and genetic bases of arterial stiffness // Hypertension. 2005. V. 45. №6. P. 1050-1055.69. https://doi.org/10.1161/01.HYP.0000164580.39991.3d
  • Quinn U., Tomlinson L. A., Cockcroft J. R. Arterial stiffness // JRSM cardiovascular disease. 2012. V. 1. №6. P. 1-8. https://doi.org/10.1258/cvd.2012.012024
  • Moshayedi H., Ahrabi R., Mardani A., Sadigetegad S., Farhudi M. Association between non-alcoholic fatty liver disease and ischemic stroke // Iranian journal of neurology. 2014. V. 13. №3. P. 144.
  • Iacobellis G., Barbarini G., Letizia C., Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects // Obesity. 2014. V. 22. №2. P. 332-336. https://doi.org/10.1002/oby.20624
  • Iaccarino G., Ciccarelli M., Sorriento D., Galasso G., Campanile A., Santulli G., Trimarco B. Ischemic neoangiogenesis enhanced by p2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system // Circulation research. 2005. V. 97. №11. P. 1182-1189. https://doi.org/10.1161/01.RES.0000191541.06788.bb
  • Mantovani A., Pernigo M., Bergamini C., Bonapace S., Lipari P., Pichiri I., Targher G. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes // PLoS One. 2015. V. 10. №8. P. e0135329
  • Goland S., Shimoni S., Zornitzki T., Knobler H., Azoulai O., Lutaty G., Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment // Journal of clinical gastroenterology. 2006. V. 40. №10. P. 949-955. https://doi.org/10.1097/01.mcg.0000225668.53673.e6
  • Trovato F. M., Martines G. F., Catalano D., Musumeci G., Pirri C., Trovato G. M. Echocardiography and NAFLD (non-alcoholic fatty liver disease) // International journal of cardiology. 2016. V. 221. P. 275-279. https://doi.org/10.1016/j.ijcard.2016.06.180
  • Rijzewijk L. J., van der Meer R. W., Smit J. W., Diamant M., Bax J. J., Hammer S., Lamb H. J. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus // Journal of the American College of Cardiology. 2008. V. 52. №22. P. 1793-1799.
  • Pisto P., Santaniemi M., Bloigu R., Ukkola O., Kesaniemi Y. A.Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study // BMJ open. 2014. V. 4. №3. P. e004973.
  • Iacobellis G., Pistilli D., Gucciardo M., Leonetti F., Miraldi F., Brancaccio G., di Gioia C. R. T. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease // Cytokine. 2005. V. 29. №6. P. 251-255. https://doi .org/10.1016/j.cyto.2004.11.002
  • Bonapace S., Valbusa F., Bertolini L., Pichiri I., Mantovani A., Rossi A., Targher G.Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus // Plos one. 2014. V. 9. №2. P. e88371. https://doi.org/10.1371/journal.pone.0088371
  • Каршина О. О., Абдилазизова Э. А. Корреляция метаболически ассоциированной жировой болезни печени с основными факторами риска сердечно-сосудистых заболеваний // Вестник Кыргызско-Российского Славянского университета. 2023. Т. 23. № 9. С. 44-50. https://doi.org/10.36979/1694-500X-2023-23-9-44-50
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp